{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.7"}]}],"title":"Adverse Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.9"}]}],"title":"Serious Adverse Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.8"}]}],"title":"Adverse Events of Special Interest"}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab (maximum 1200 milligrams \\[mg\\]) on Day 1 of each 21-day cycle.","id":"OG000","title":"Atezolizumab"}],"paramType":"NUMBER","populationDescription":"Included safety-evaluable population, defined as patients who received any amount of study drug.","reportingStatus":"POSTED","timeFrame":"From baseline up to approximately 42 months","title":"Percentage of Participants Adverse Events, Serious Adverse Events and Adverse Events of Special Interest","type":"PRIMARY","unitOfMeasure":"Percentage"}